Ideal Tacrolimus Levels After Living Donor Liver Transplantation

Introduction to Tacrolimus Levels

The American College of Transplantation suggests maintaining tacrolimus trough levels at 6-10 ng/mL during the first month post-transplant, then reducing to 4-8 ng/mL for long-term maintenance, with evidence suggesting levels as low as 4.6 ng/mL remain safe and may improve renal outcomes 1

The American Society of Transplantation recommends maintaining tacrolimus trough levels at 6-10 ng/mL during the initial month when rejection risk is highest 1, 2
Monitor trough levels daily until target is reached, then every 2-3 days until hospital discharge, as recommended by the American College of Transplantation 1

The American Association for the Study of Liver Diseases suggests reducing target trough levels to 4-8 ng/mL after the first month, with most patients maintained around 5 ng/mL after one year on monotherapy 3, 1

The National Kidney Foundation recommends using lower trough levels than monotherapy when combining tacrolimus with basiliximab induction and/or mycophenolate/azathioprine to preserve renal function 1
Consider basiliximab with MMF or azathioprine to allow 5-day delay in tacrolimus introduction for patients at high risk of post-transplant renal dysfunction, as suggested by the American College of Transplantation 1

Nephrotoxicity represents a major cause of morbidity and mortality after liver transplant, with renal insufficiency being dose-dependent, according to the American Journal of Transplantation 4, 3
Over half of deaths in liver transplant patients relate to complications from immunosuppression including cardiovascular disease, renal failure, infection, and malignancy, as reported by the American Journal of Transplantation 4

Exercise extreme caution when switching tacrolimus formulations, as this may precipitate rejection; increase monitoring frequency with any formulation change, as recommended by the American Association for the Study of Liver Diseases 3, 1

For patients at high risk of post-transplant renal dysfunction, the American Association for the Study of Liver Diseases recommends using basiliximab induction with mycophenolate mofetil or azathioprine to delay tacrolimus introduction by 5 days 5
When using combination immunosuppression, target lower tacrolimus trough levels (4-7 ng/mL during first month, then 3-5 ng/mL) to preserve renal function 5

Beyond the first year, most patients can be maintained on 4-6 ng/mL with monotherapy, according to the American Association for the Study of Liver Diseases 5

Minimize CNI exposure by employing combination immunosuppressive regimens, preferably mTOR inhibitor-based, in patients with high risk of hepatic or extrahepatic cancer recurrence, as recommended by the American Association for the Study of Liver Diseases 5
mTOR inhibitor-based immunosuppression is strongly recommended for patients with history of recurrent/de novo non-melanoma skin cancer, according to the American Association for the Study of Liver Diseases 5
Screen for preformed donor-specific antibodies in recipients at risk of humoral sensitization, and monitor for de novo DSAs combined with ALT and transient elastography to identify subclinical rejection risk, particularly when considering aggressive immunosuppression minimization, as recommended by the American Association for the Study of Liver Diseases 5

Do not minimize immunosuppression aggressively in patients with high mean fluorescence intensity DSAs unless allograft damage has been excluded by liver biopsy, according to the American Association for the Study of Liver Diseases 5
Consider renal-sparing combination regimens for high-risk patients rather than tacrolimus monotherapy, as recommended by the American Association for the Study of Liver Diseases 5